Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Raju Subramanian

Showing results (51-60 of 76) with videos related to

Pageof 8
Sort By:
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 21, 2012
Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzymeKirk R Henne, Thuy B Tran, Brooke M VandenBrink, et al.
Chemical Research in Toxicology|January 26, 2010
Cytochrome P450-mediated epoxidation of 2-aminothiazole-based AKT inhibitors: identification of novel GSH adducts and reduction of metabolic activation through structural changes guided by in silico and in vitro screeningRaju Subramanian, Matthew R Lee, John G Allen, et al.
Clinical Pharmacology and Therapeutics|June 28, 2024
Pharmacokinetics, Mass Balance, Safety, and Tolerability of Obeldesivir in Healthy ParticipantsOlena Anoshchenko, Mazin Abdelghany, Amos Lichtman, et al.
Bioorganic & Medicinal Chemistry Letters|August 24, 2015
The imidazo[1,2-a]pyridine ring system as a scaffold for potent dual phosphoinositide-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitorsMarkian M Stec, Kristin L Andrews, Yunxin Bo, et al.
Antiviral Research|May 7, 2022
Intravenous delivery of GS-441524 is efficacious in the African green monkey model of SARS-CoV-2 infectionJared Pitts, Darius Babusis, Meghan S Vermillion, et al.
Journal of Medicinal Chemistry|July 1, 2011
Structure-activity relationships of phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors: investigations of various 6,5-heterocycles to improve metabolic stabilityMarkian M Stec, Kristin L Andrews, Shon K Booker, et al.
Molecular Pharmaceutics|November 2, 2023
Lenacapavir: A Novel, Potent, and Selective First-in-Class Inhibitor of HIV-1 Capsid Function Exhibits Optimal Pharmacokinetic Properties for a Long-Acting Injectable Antiretroviral AgentRaju Subramanian, Jennifer Tang, Jim Zheng, et al.
Antiviral Research|January 15, 2022
Subcutaneous remdesivir administration prevents interstitial pneumonia in rhesus macaques inoculated with SARS-CoV-2Brandi N Williamson, Lizzette Pérez-Pérez, Benjamin Schwarz, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 19, 2005
Induction of CYP1A in the beagle dog by an inhibitor of kinase insert domain-containing receptor: differential effects in vitro and in vivo on mRNA and functional activityChristopher R Gibson, Charles Lin, Rominder Singh, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 8, 2024
Lenacapavir Exhibits Atropisomerism-Mechanistic Pharmacokinetics and Disposition Studies of Lenacapavir Reveal Intestinal Excretion as a Major Clearance PathwayJim Zheng, Bing Lu, Gavin Carr, et al.
Pageof 8

Showing results (51-60 of 76) with videos related to

Sort By:
Pageof 8
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 21, 2012
Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzymeKirk R Henne, Thuy B Tran, Brooke M VandenBrink, et al.
Chemical Research in Toxicology|January 26, 2010
Cytochrome P450-mediated epoxidation of 2-aminothiazole-based AKT inhibitors: identification of novel GSH adducts and reduction of metabolic activation through structural changes guided by in silico and in vitro screeningRaju Subramanian, Matthew R Lee, John G Allen, et al.
Clinical Pharmacology and Therapeutics|June 28, 2024
Pharmacokinetics, Mass Balance, Safety, and Tolerability of Obeldesivir in Healthy ParticipantsOlena Anoshchenko, Mazin Abdelghany, Amos Lichtman, et al.
Bioorganic & Medicinal Chemistry Letters|August 24, 2015
The imidazo[1,2-a]pyridine ring system as a scaffold for potent dual phosphoinositide-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitorsMarkian M Stec, Kristin L Andrews, Yunxin Bo, et al.
Antiviral Research|May 7, 2022
Intravenous delivery of GS-441524 is efficacious in the African green monkey model of SARS-CoV-2 infectionJared Pitts, Darius Babusis, Meghan S Vermillion, et al.
Journal of Medicinal Chemistry|July 1, 2011
Structure-activity relationships of phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors: investigations of various 6,5-heterocycles to improve metabolic stabilityMarkian M Stec, Kristin L Andrews, Shon K Booker, et al.
Molecular Pharmaceutics|November 2, 2023
Lenacapavir: A Novel, Potent, and Selective First-in-Class Inhibitor of HIV-1 Capsid Function Exhibits Optimal Pharmacokinetic Properties for a Long-Acting Injectable Antiretroviral AgentRaju Subramanian, Jennifer Tang, Jim Zheng, et al.
Antiviral Research|January 15, 2022
Subcutaneous remdesivir administration prevents interstitial pneumonia in rhesus macaques inoculated with SARS-CoV-2Brandi N Williamson, Lizzette Pérez-Pérez, Benjamin Schwarz, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 19, 2005
Induction of CYP1A in the beagle dog by an inhibitor of kinase insert domain-containing receptor: differential effects in vitro and in vivo on mRNA and functional activityChristopher R Gibson, Charles Lin, Rominder Singh, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 8, 2024
Lenacapavir Exhibits Atropisomerism-Mechanistic Pharmacokinetics and Disposition Studies of Lenacapavir Reveal Intestinal Excretion as a Major Clearance PathwayJim Zheng, Bing Lu, Gavin Carr, et al.
Pageof 8